Dr. Reddy's Laboratories Limited (DRREDDY) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,385 (+1.09% day change)
Key ratios
- P/E ratio
- 26.9
- P/B ratio
- 2.77
- ROE (%)
- 11.36
- ROCE (%)
- 11.28
- Debt/Equity
- 0.24
- Dividend yield (%)
- 0.64
- Market cap (₹ Cr)
- 115,363.48
Forensic checks
Piotroski F-Score: 3/9 · Altman Z-Score: 9.28 · Beneish M-Score: -2.21
InvestSights quality score
64.8/100 — Above Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- SG&A as % of sales: guided 27.5–28%, delivered 28.1% (FY25) — missed guidance
- R&D as % of sales: guided 8.5–9%, delivered 7.5% (FY26) — missed guidance
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from this call is that Dr. Reddy's semaglutide injectable supply programme has encountered a meaningful but management-characterised-as-temporary setback: a process-related out-of-specification impurity detected during scale-up validation has halted commercial API dispatch for approximately three months (July–September 2026), compressing the…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.